Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. A Prospective, Mono-center, Placebo- and Active Treatment-controlled, Randomized, Cross Over Study. (DOSAPI)

NCT01175200 NA COMPLETED

This study will establish the optimal therapeutic strategy for patients with a coronary artery disease (CAD) and chronically treated with clopidogrel 75 mg/day requiring co-administration of an anti-platelet treatment with P2Y12 antagonist and a PPI for treatment/prevention of GI ulceration.

Details

Lead sponsor	Ascopharm Groupe Novasco
Phase	NA
Status	COMPLETED
Enrolment	82
Start date	2010-09
Completion	2012-07

Conditions

• Anti Platelet Effects

Interventions

• Clopidogrel
• Prasugrel
• Lansoprazole
• Placebo

Primary outcomes

• Change in antiplatelet effect of clopidogrel — 14 days
  change in antiplatetelet effect of clopidogrel as compared to prasugrel when associated to lansoprazole (or placebo) in patients with stable angina

Countries

France